Navigation Links
CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Date:1/30/2008

PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release fourth quarter and year end financial results for 2007 after the market closes on Tuesday, February 26, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Tiany...), a manufacturer and supplier,of modernized trad... China,today announced the implementation of a n...h distributors and hospital clients into three cla...ng structure. , The new strategy has classi...
(Date:12/2/2008)...to File NDA with FDA in Early to Mid-2009 , ,...all/ -- Strativa Pharmaceuticals, the proprietary ... Inc. (NYSE: PRX ) today announced that its deve...ul completion of all pivotal bioequivalence studie...ondansetron thin film product is being developed f...
(Date:12/2/2008)...H, Mich., Dec. 2 GeneGo, Inc., the...today that Burnham has become a certified GeneGo C... institution-wide access to GeneGo,s MetaCore data...he Burnham institute is a world-class biomedical r...al studies throughout many departments, including ...
(Date:12/2/2008)... CARMEL, Israel, December 2 InSigh...ow that Magnetic Resonance-guided Focused,Ultraso...otential to be an,effective noninvasive pain-reli...e bones (bone metastases). The results of a 31 pat... of Annals of Surgical Oncology, while data from a...
Breaking Biology Technology:Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 4The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4
...in-based health care imaging software and services... PACS version 1.2.7. The new version features enh...on tools, image viewer plug-in and automated acces...d an electronic medical record makes provision of ...desktop highly desirable," said William Stafford, ...
...nology Council has published the first-ever magazi...-page publication highlights the states research b..., quality of life, key contacts and the I-Q Corrid...t. Paul. , ,The Wisconsin Technology Network has ...onsin The Smart Choice, over the next few weeks. ...
...an, president and CEO of the University of Wiscons...cal affairs for UW Medical School was the kick-off.... In this interview with WTN, Dr. Grossman discuss...lumes of data but, at the same time a Knowledge Ga...n is board certified in internal medicine, pulmona...
...nce Sept. 16-17 at the Monona Terrace on how games...aims to present successful projects in which games...s Initiative , the Academic Advanced Distributed ...ientists Learning Federation Project are co-spon...lity development of a new generation of game-based...
Other Biology Technology:Life Science: From Chicago to the Twin Cities: All tech roads lead to Wisconsin 2Life Science: From Chicago to the Twin Cities: All tech roads lead to Wisconsin 3WTN interview: Dr. Jeffrey Grossman, CEO UW Medical Foundation 2WTN interview: Dr. Jeffrey Grossman, CEO UW Medical Foundation 3WTN interview: Dr. Jeffrey Grossman, CEO UW Medical Foundation 4WTN interview: Dr. Jeffrey Grossman, CEO UW Medical Foundation 5
(Date:12/2/2008)...OUSTON, Dec. 2, 2008 Scientists and engineers fro... and energy will come together Dec. 8, along with...xplore synergies in moving oil and pumping blood. ... heart must pump blood through the body. Both sys...vessels), free of blockages or corrosion, to funct...
(Date:12/2/2008)...ew Haven, Conn.Organizations in the United States ...from climate change are not adapting enough to the...o a Yale report. , "Despite a half century of cl...ed temperature and precipitation patterns and has ... impacts, and despite a near certainty that the Un...
(Date:12/2/2008)...msterdam, 2 December 2008 - Elsevier is delighted ... be the official publisher of the quarterly peer-r...t ( www.elsevier.com/locate/esd ) on behalf of th...tainable development involves meeting present huma...ations. Energy is central to providing many of the...
(Date:12/2/2008)...erforming systematic reviews of nutrition related ...red in the field of medicine. In a new article, a ...ibe the steps, strengths, and limitations of syste...e factors that impact the results. , Systematic...ws, provide objective assessments with pre-specifi...
Breaking Biology News(10 mins):Using the other guy's toolkit: Similarities of pumping blood, oil examined 2Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3New publishing partnership for Energy for Sustainable Development 2Experts discuss applying systematic review to the field of nutrition 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx 28R 29 GENTAMICIN TOPICAL for the Treatment of Moderate 1835 1Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx 28R 29 GENTAMICIN TOPICAL for the Treatment of Moderate 1835 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx 28R 29 GENTAMICIN TOPICAL for the Treatment of Moderate 1835 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx 28R 29 GENTAMICIN TOPICAL for the Treatment of Moderate 1835 4Compensation Risk Managers LLC Receives Notice of Administrative Action by New York Workers Compensation Board 17061 1Compensation Risk Managers LLC Receives Notice of Administrative Action by New York Workers Compensation Board 17061 2Compensation Risk Managers LLC Receives Notice of Administrative Action by New York Workers Compensation Board 17061 3ACS Systems Improving Delivery of Healthcare in Malta 17060 1ACS Systems Improving Delivery of Healthcare in Malta 17060 2ACS Systems Improving Delivery of Healthcare in Malta 17060 3Limited transparency in federal nanotech research may hamper development 4665 1Limited transparency in federal nanotech research may hamper development 4665 2
...ublished this week report findings that increase o... determined and how the speed of its development i...on the molecular and cellular pathways that act to...e, as well as on pathways that use that informatio...uring development. , The two studies are reported ...
...w ,dwarf belonging to the sea, in laboratoryScient...ir thinking about how Archaea, an ancient kingdom ...aintaining the global balance of nitrogen and carb... known to oxidize ammonia for energy and metaboliz...tively named, Nitrosopumilus maritimus, in the lab...
...w species, a team of international scientists leav... undiscovered treasures in the Mountains of Southw...ntain range. , "Expedition Everest: Mission Himal...ore one of the planet,s richest and most biologica...ith a month-long exploration in China where scient...
...irst medical uses of nanotechnology, a chemist and...diseases have joined forces to create an early det...most common cause of hospitalization among childre...sends about 120,000 children to the hospital in th...e-threatening in one case out of every 100, it inf...
Other Biology News:Hormones and growth: The control of body size and developmental growth rate in fruit flies 2Marine bacterium suspected to play role in global carbon and nitrogen cycles 2Team of international scientists departs today to discover the unknown in China's Himalayan region 2Team of international scientists departs today to discover the unknown in China's Himalayan region 3Quantum dots provide a faster, more sensitive method for detecting respiratory viral infections 2Quantum dots provide a faster, more sensitive method for detecting respiratory viral infections 3Quantum dots provide a faster, more sensitive method for detecting respiratory viral infections 4
ANTI ALPHA FSH:B
Beagle Serum • Beagle serum is collected from fasted Beagle canines of mixed sex over one year of age Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Pot
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein
MOUSE ANTI BOVINE TROPONIN I
Biology Products: